Radiation shielding is the process of limiting the penetration of radiation into the environment, by blocking with a barrier made of impermeable material. This protective barrier is usually formed of a material with high density, for example lead that absorbs the radiation.
Radiation sources are self-shielded with absorbing material incorporated into the equipment, adjacent to the source to reduce stray radiation to the surrounding area below dose limits.
Rooms with x-ray or other radiation equipment are additionally shielded with lead-lined walls to reduce the radiation exposure to humans within the facility. The amount of shielding required to protect against different kinds of radiation depends on how much energy they have. The shielding calculations are based on the half value layer of the primary radiation beam. Sufficient half value layers of shielding are calculated to reduce the radiation exposure outside the room to reasonable levels.
Personal shielding requirements depending on the type of radiation:
See also Radiation Safety.

Contrast media injectors are part of the medical equipment used to deliver fluids in examinations such as CT, MRI, fluoroscopy and angiography. Many of these diagnostic imaging procedures include the administration of intravenous contrast agents to enhance the blood and perfusion in tissues.

Mainly there are two types of injector technology:
See also Single-Head Contrast Media Injector, Dual-Head CT Power Injector, Syringeless CT Power Injector.

The use of x-ray contrast agents in computed tomography (CT) began with a hand injection by the radiologist in the scan room. During its history, CT scanners have made great improvements in speed and image quality. Actual CT systems with multiple detectors allow scan times of a few seconds per body region. Some CT protocols require multiphase scans, where a body region is imaged with a single bolus of contrast in different blood flow phases. Automatic power (pressure) contrast media injectors are required to provide precise control of flow rate, volume and timing of injection. The use of a saline bolus following contrast administration reduces the volume of contrast required.

Most relevant topics for the use of a power injector in medical imaging procedures such as contrast enhanced computed tomography (CECT):
Must have basic injector control options:
Examples of other injector control options:

(ALARA) 'As low as reasonably achievable' is a precautionary principle that should be part of basic radiation safety considerations in protection to the exposure as well as in other technologies of the medical, the nuclear and the industrial fields.
ALARA is based on three principles: Justification means that possible exposure to humans should yield a sufficient benefit to society to justify the risks of the radiation exposure. The ICRP in 1977 states that 'all exposures shall be kept as low as reasonably achievable, economic and social factors being taken into account'. The radiation exposure must be reduced to the lowest level possible, considering the costs of such a limitation in dose.

(LCR) The low contrast resolution describes the ability to discriminate between tissues with slightly differences in attenuation properties. The LCR depends on the stochastic noise.
The low contrast resolution is usually expressed as the minimum detectable size of an image structure, for a fixed percentage difference in contrast relative to the adjacent background.
A strength of computed tomography (CT) is its ability to visualize structures of low contrast in an object, a task that is limited by noise and is closely associated with the radiation dose. For example, a reduction of the dose at constant spatial resolution affects the visibility of structures with low contrast (e.g. vessels in the liver), due to increased noise. The visibility of these low contrast structures can partly be improved by decreasing the spatial resolution, while keeping the dose constant.

See also CT Number, Image Quality and Low Contrast Detectability.

Different stages of testing drugs in humans, from first application in humans through limited and broad clinical tests, to postmarketing studies. Preclinical trials are the testing in animals.